Australian data do not support current Pharmaceutical Benefits Scheme criteria for use of tumour necrosis factor-alpha inhibitors in ankylosing spondylitis.
Schachna
L
L
Brown
M A
MA
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001315:Australia; D006801:Humans; D009363:Neoplasm Proteins / Q000627:therapeutic use*; D010593:Pharmaceutical Services / Q000191:economics; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000627:therapeutic use*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D053319:Tumor Necrosis Factor Decoy Receptors
D018501:Antirheumatic Agents; D009363:Neoplasm Proteins; D047889:Receptors, Tumor Necrosis Factor, Type II; D053319:Tumor Necrosis Factor Decoy Receptors